Devices & Diagnostics AtriCure targets fourth quarter to begin stroke trial enrollment By Brandon Glenn
Devices & Diagnostics AtriCure aims to grab more cardiac ablation market share from Medtronic By Brandon Glenn
Devices & Diagnostics AtriCure: Training surgeons for AF procedure takes on big importance By Brandon Glenn
Devices & Diagnostics AtriCure again cited by an analyst as likely acquisition target By Brandon Glenn
Devices & Diagnostics AtriCure closes enrollment in ‘hybrid’ atrial fibrillation study By Brandon Glenn
Devices & Diagnostics AtriCure expects FDA approval of atrial fibrillation surgical label in Q1 By Brandon Glenn
Devices & Diagnostics AtriCure shares soar on FDA atrial fibrillation recommendation By Brandon Glenn
Devices & Diagnostics Analyst: AtriCure among most likely medical device acquisition targets By Brandon Glenn
Devices & Diagnostics AtriCure: FDA panel to review application for atrial fibrillation label By Brandon Glenn
Devices & Diagnostics AtriCure: Is now the time for a strategic acquirer to step up? By Brandon Glenn
Devices & Diagnostics AtriCure expects FDA clearance of new cryoablation system next quarter By Brandon Glenn
